BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 31356213)

  • 1. Classification of Clinically Diagnosed Alzheimer's Disease Associated with Diabetes Based on Amyloid and Tau PET Results.
    Takenoshita N; Shimizu S; Kanetaka H; Sakurai H; Suzuki R; Miwa T; Odawara M; Ishii K; Shimada H; Higuchi M; Suhara T; Hanyu H
    J Alzheimers Dis; 2019; 71(1):261-271. PubMed ID: 31356213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amyloid and Tau Positron Emission Tomography in Suggested Diabetesrelated Dementia.
    Takenoshita N; Fukasawa R; Ogawa Y; Shimizu S; Umahara T; Ishii K; Shimada H; Higuchi M; Suhara T; Hanyu H
    Curr Alzheimer Res; 2018; 15(11):1062-1069. PubMed ID: 29984653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tau Accumulation in Clinically Normal Older Adults Is Associated with Hippocampal Hyperactivity.
    Huijbers W; Schultz AP; Papp KV; LaPoint MR; Hanseeuw B; Chhatwal JP; Hedden T; Johnson KA; Sperling RA
    J Neurosci; 2019 Jan; 39(3):548-556. PubMed ID: 30482786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct amyloid and tau PET signatures are associated with diverging clinical and imaging trajectories in patients with amnestic syndrome of the hippocampal type.
    Lagarde J; Olivieri P; Tonietto M; Gervais P; Comtat C; Caillé F; Bottlaender M; Sarazin M
    Transl Psychiatry; 2021 Sep; 11(1):498. PubMed ID: 34588422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subgroups of Alzheimer's disease associated with diabetes mellitus based on brain imaging.
    Fukazawa R; Hanyu H; Sato T; Shimizu S; Koyama S; Kanetaka H; Sakurai H; Iwamoto T
    Dement Geriatr Cogn Disord; 2013; 35(5-6):280-90. PubMed ID: 23594859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Visual cognition in non-amnestic Alzheimer's disease: Relations to tau, amyloid, and cortical atrophy.
    Putcha D; Brickhouse M; Touroutoglou A; Collins JA; Quimby M; Wong B; Eldaief M; Schultz A; El Fakhri G; Johnson K; Dickerson BC; McGinnis SM
    Neuroimage Clin; 2019; 23():101889. PubMed ID: 31200149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitochondrial complex I abnormalities is associated with tau and clinical symptoms in mild Alzheimer's disease.
    Terada T; Therriault J; Kang MSP; Savard M; Pascoal TA; Lussier F; Tissot C; Wang YT; Benedet A; Matsudaira T; Bunai T; Obi T; Tsukada H; Ouchi Y; Rosa-Neto P
    Mol Neurodegener; 2021 Apr; 16(1):28. PubMed ID: 33902654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
    Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brain Amyloid-β Deposition and Blood Biomarkers in Patients with Clinically Diagnosed Alzheimer's Disease.
    Li WW; Shen YY; Tian DY; Bu XL; Zeng F; Liu YH; Chen Y; Yao XQ; Li HY; Chen DW; Zhou FY; Yang H; Li QM; Bao WQ; Guan YH; Zhou HD; Jin RB; Wang YJ
    J Alzheimers Dis; 2019; 69(1):169-178. PubMed ID: 30958377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Critical Comparison of Different Biomarkers for Alzheimer's Disease in a Clinical Setting.
    Weise D; Tiepolt S; Awissus C; Hoffmann KT; Lobsien D; Kaiser T; Barthel H; Sabri O; Gertz HJ
    J Alzheimers Dis; 2015; 48(2):425-32. PubMed ID: 26402006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of diabetes-related dementia: Longitudinal perfusion SPECT and amyloid PET studies.
    Fukasawa R; Hanyu H; Shimizu S; Kanetaka H; Sakurai H; Ishii K
    J Neurol Sci; 2015 Feb; 349(1-2):45-51. PubMed ID: 25573776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feasibility and acceptance of simultaneous amyloid PET/MRI.
    Schütz L; Lobsien D; Fritzsch D; Tiepolt S; Werner P; Schroeter ML; Berrouschot J; Saur D; Hesse S; Jochimsen T; Rullmann M; Sattler B; Patt M; Gertz HJ; Villringer A; Claßen J; Hoffmann KT; Sabri O; Barthel H
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2236-2243. PubMed ID: 27435367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concordance and Diagnostic Accuracy of [11C]PIB PET and Cerebrospinal Fluid Biomarkers in a Sample of Patients with Mild Cognitive Impairment and Alzheimer's Disease.
    Leuzy A; Carter SF; Chiotis K; Almkvist O; Wall A; Nordberg A
    J Alzheimers Dis; 2015; 45(4):1077-88. PubMed ID: 25649653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brain metabolic correlates of CSF Tau protein in a large cohort of Alzheimer's disease patients: A CSF and FDG PET study.
    Chiaravalloti A; Barbagallo G; Ricci M; Martorana A; Ursini F; Sannino P; Karalis G; Schillaci O
    Brain Res; 2018 Jan; 1678():116-122. PubMed ID: 29066367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regional Tau Correlates of Instrumental Activities of Daily Living and Apathy in Mild Cognitive Impairment and Alzheimer's Disease Dementia.
    Marshall GA; Gatchel JR; Donovan NJ; Muniz MC; Schultz AP; Becker JA; Chhatwal JP; Hanseeuw BJ; Papp KV; Amariglio RE; Rentz DM; Sperling RA; Johnson KA
    J Alzheimers Dis; 2019; 67(2):757-768. PubMed ID: 30689584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pittsburgh Compound B and AV-1451 positron emission tomography assessment of molecular pathologies of Alzheimer's disease in progressive supranuclear palsy.
    Whitwell JL; Ahlskog JE; Tosakulwong N; Senjem ML; Spychalla AJ; Petersen RC; Jack CR; Lowe VJ; Josephs KA
    Parkinsonism Relat Disord; 2018 Mar; 48():3-9. PubMed ID: 29254665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic Effect of Serum Homocysteine and Diabetes Mellitus on Brain Alterations.
    Byeon G; Byun MS; Yi D; Lee JH; Jeon SY; Ko K; Jung G; Lee JY; Kim YK; Lee YS; Kang KM; Sohn CH; Lee DY;
    J Alzheimers Dis; 2021; 81(1):287-295. PubMed ID: 33749655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages.
    Schwarz AJ; Yu P; Miller BB; Shcherbinin S; Dickson J; Navitsky M; Joshi AD; Devous MD; Mintun MS
    Brain; 2016 May; 139(Pt 5):1539-50. PubMed ID: 26936940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spreading of amyloid, tau, and microvascular pathology in Alzheimer's disease: findings from neuropathological and neuroimaging studies.
    Thal DR; Attems J; Ewers M
    J Alzheimers Dis; 2014; 42 Suppl 4():S421-9. PubMed ID: 25227313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imaging in-vivo tau pathology in Alzheimer's disease with THK5317 PET in a multimodal paradigm.
    Chiotis K; Saint-Aubert L; Savitcheva I; Jelic V; Andersen P; Jonasson M; Eriksson J; Lubberink M; Almkvist O; Wall A; Antoni G; Nordberg A
    Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1686-99. PubMed ID: 26996778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.